Proceeds will fund clinical development of oncology and immunology therapeutics derived from innovative antibody payload platform Mark Throsby, industry veteran and former CSO of Merus, joins as Executive Chair EQT Life Sciences is pleased to announce that its LSP 7 fund has invested in ATB Therapeutics. The €54 million …
